Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05239975
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:58.901730+00:00
Published At
2024-02-09T00:00:00+00:00
Record Updated At
2024-02-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["COVID-19", "SARS-CoV2 Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-02-09"
protocolSection.identificationModule.nctId
"NCT05239975"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged \u226512 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • COVID-19 (protocolSection.conditionsModule.conditions)
  • SARS-CoV2 Infection (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.